UCB SA (OTCMKTS:UCBJF) Given Consensus Rating of “Moderate Buy” by Brokerages

UCB SA (OTCMKTS:UCBJF) has earned an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company.

A number of analysts have weighed in on UCBJF shares. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd.

UCB Stock Performance

Shares of UCB stock opened at $254.59 on Friday. The company has a 50 day moving average of $286.81 and a 200-day moving average of $296.99. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a 1-year low of $219.50 and a 1-year high of $345.39.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.